- Home
- ECOR vs BEAT Comparison
ECOR vs BEAT Comparison
Compare ECOR & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- BEAT
- Stock Information
- Founded
- ECOR 2005
- BEAT 2015
- Country
- ECOR United States
- BEAT United States
- Employees
- ECOR N/A
- BEAT 20
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- ECOR Health Care
- BEAT Technology
- Exchange
- ECOR Nasdaq
- BEAT Nasdaq
- Market Cap
- ECOR 65.0M
- BEAT 74.1M
- IPO Year
- ECOR 2018
- BEAT 2021
- Fundamental
- Price
- ECOR $16.49
- BEAT $2.68
- Analyst Decision
- ECOR Strong Buy
- BEAT Buy
- Analyst Count
- ECOR 1
- BEAT 1
- Target Price
- ECOR $15.00
- BEAT $8.00
- AVG Volume (30 Days)
- ECOR 97.7K
- BEAT 282.2K
- Earning Date
- ECOR 11-13-2024
- BEAT 11-07-2024
- Dividend Yield
- ECOR N/A
- BEAT N/A
- EPS Growth
- ECOR N/A
- BEAT N/A
- EPS
- ECOR N/A
- BEAT N/A
- Revenue
- ECOR $23,327,000.00
- BEAT N/A
- Revenue This Year
- ECOR $61.40
- BEAT N/A
- Revenue Next Year
- ECOR $38.43
- BEAT N/A
- P/E Ratio
- ECOR N/A
- BEAT N/A
- Revenue Growth
- ECOR 74.10
- BEAT N/A
- 52 Week Low
- ECOR $5.25
- BEAT $1.06
- 52 Week High
- ECOR $15.25
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- ECOR 69.93
- BEAT 47.14
- Support Level
- ECOR $13.22
- BEAT $2.28
- Resistance Level
- ECOR $14.87
- BEAT $3.48
- Average True Range (ATR)
- ECOR 1.34
- BEAT 0.29
- MACD
- ECOR 0.30
- BEAT -0.05
- Stochastic Oscillator
- ECOR 87.04
- BEAT 37.83
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.